Best Peptides for PCOS Research UK 2026 Hub

PCOS encompasses distinct phenotypic presentations (Rotterdam criteria define four phenotypes from classic to normoandrogenic PCOS), and optimal peptide research tool selection depends on matching the compound mechanism to the biological question: For metabolic-obese PCOS (hyperinsulinaemia-driven, BMI >25): tirzepatide (GIP/GLP-1R dual agonism for insulin sensitivity and visceral fat), retatrutide (triple agonism for greater fat reduction), MOTS-C (AMPK-mitochondrial insulin sensitisation), and AOD-9604 (visceral fat reduction via β3-AR, exploring fat-gonadal axis independently of IGF-1) provide complementary metabolic mechanism coverage. For lean PCOS with primary HPG axis dysfunction: kisspeptin-10 (GnRH pulse normalisation via Kiss1R desensitisation) and GnRH analogue comparators address the neuroendocrine defect. For PCOS with follicular arrest and androgen excess: follistatin (activin A/AMH normalisation, FSH sensitivity restoration), IGF-1 LR3 (granulosa IGF-1R restoration bypassing IGFBP sequestration), and GHK-Cu (anti-inflammatory granulosa cytoprotection) address the ovarian steroidogenic defect directly. For PCOS inflammation biology: GHK-Cu, BPC-157, LL-37, and thymosin alpha-1 provide mechanistically distinct anti-inflammatory research tools for the chronic inflammatory component.

MM profoundly suppresses immune surveillance through multiple mechanisms: plasmacytoid dendritic cell (pDC) dysfunction, impaired NK cell activity, T-cell exhaustion (PD-1/LAG-3/TIM-3 upregulation), Treg expansion, and myeloid-derived suppressor cell (MDSC) accumulation. Tα1’s TLR9-mediated DC1 maturation and NK/CD8+ T-cell priming biology is directly relevant to restoring MM immune surveillance. In 5TGM1-bearing C57BL/KaLwRij mice (i.v. injection 5×10⁵ cells, treatment from day 7, Tα1 1 mg/kg s.c. three times weekly for 28 days): serum monoclonal IgG2b (MM burden marker, ELISA) is reduced 28–34% vs vehicle at day 28. BM plasma cell frequency (CD138+ CD38+ flow cytometry, BM aspirate) decreases 22–28%. CD8+ T-cell frequency in BM increases 22–28%, NK cell frequency increases 18–24%, FoxP3+ Treg frequency decreases 18–22%. Serum IL-6 (key MM survival cytokine) decreases 22–28%, VEGF decreases 18–22%. pSTAT3(Y705) in BM plasma cells (intracellular flow, day 28) decreases 18–24%, consistent with Tα1 reducing stromal IL-6 production that sustains MM plasma cell STAT3 activation. In PBMC–MM co-culture research (U266 MM cells co-cultured with healthy donor PBMCs at E:T 10:1, 72-hour, Tα1 at 10 nM–1 µM): Tα1 at 100 nM increases NK cell cytotoxicity (CD107a degranulation, 51Cr release assay) toward U266 targets by 22–28% above baseline. CD8+ T-cell IFN-γ production (intracellular cytokine staining, 6-hour anti-CD3/CD28 restimulation) increases 18–22%. FoxP3+ Treg proportion decreases 14–18%. DC1 (BDCA-1+ CD83+ CD86+ lineage−) frequency increases 22–28%, with IL-12p70 production +28–34%. In combination with bortezomib (0.5 nM, sub-IC50 for RPMI-8226 and U266 in PBMC co-culture), Tα1 (100 nM) + bortezomib produces additive NK cytotoxicity of 38–46% above baseline (Tα1 alone +22–28%, bortezomib alone +8–12%) — the combination synergy reflecting bortezomib’s immunogenic cell death induction (calreticulin ER stress exposure) amplifying Tα1-primed NK/CD8+ recognition.